Spliceostatin A and its analog meayamycin B target splicing factor SF3B1 and inhibit formation of the p61 BRAF V600E splice variant, which in turn re-sensitizes therapy-resistant melanomas to vemurafenib as demonstrated in both in vitro and in vivo models (Figure 4A) [154]. This evidence concerns the gene BRAF and melanoma.